Hyperbaric Chamber for Asthma: What Patients Need to Know

Asthma is a condition of airway inflammation and bronchospasm, and the idea that high-oxygen therapy might help seems intuitive to many patients. The reality is more complicated. HBOT is not an established treatment for asthma, and in some situations it carries specific risks for asthmatic patients. Understanding this clearly, before pursuing treatment, is essential for patient safety. Here’s what is actually known. It is one of several broader spectrum of chronic conditions and HBOT that researchers are actively investigating.

Asthma’s Mechanism and Why HBOT Is a Theoretically Interesting Question

Asthma involves chronic airway inflammation, bronchial hyperresponsiveness, and reversible bronchoconstriction. During attacks, the airways narrow due to smooth muscle spasm and mucosal inflammation, reducing oxygen delivery to alveoli. Between attacks, the underlying inflammation persists even when symptoms are absent.

HBOT’s anti-inflammatory properties are theoretically relevant. By suppressing pro-inflammatory cytokines and NF-kB signaling, HBOT has been shown to reduce inflammation in various tissues. Whether these effects extend meaningfully to the airway epithelium and reduce asthma’s characteristic airway inflammation is the key question.

What Does the Research Say?

Clinical research on HBOT for asthma is very limited and not of high quality.

Small Studies

A small number of studies, primarily from Russian and Eastern European institutions, have examined HBOT in asthma patients. These have generally reported improvements in bronchial responsiveness testing, reductions in inflammatory markers (eosinophils, IgE), and patient-reported symptom scores. One study documented reduced frequency of asthma attacks and reduced bronchodilator use after a course of HBOT.

These results are intriguing but come from small studies without adequate control groups or blinding. They cannot establish whether the improvements were specific to HBOT or due to non-specific effects of intensive clinical attention, spontaneous symptom fluctuation, or other concurrent management improvements.

What’s Missing

There are no large randomized controlled trials of HBOT for asthma. Neither the American Thoracic Society nor GINA (Global Initiative for Asthma) includes HBOT in asthma management guidelines. The evidence does not come close to the standard required for clinical recommendation.

What Are the Side Effects and Risks?

Air Trapping Risk

During pressurization in a hyperbaric chamber, trapped air in closed spaces expands as pressure changes. In patients with asthma who have significant air trapping, particularly those with mucus plugging or severe bronchospasm, there is a theoretical risk of alveolar overdistension or rupture during chamber entry or exit (decompression). This risk is highest during acute asthma exacerbations or in patients with severe, poorly controlled asthma.

Well-controlled asthma in stable patients presents a lower (though not zero) risk. The decision to proceed with HBOT in asthmatic patients requires pulmonologist evaluation, current spirometry, and confirmation of disease control status.

Oxygen-Induced Bronchospasm

A small proportion of people with asthma experience paradoxical bronchospasm when exposed to high concentrations of inhaled oxygen. This is uncommon but worth discussing with the hyperbaric physician before treatment. A bronchodilator administered before the session may be appropriate.

During Acute Exacerbations

HBOT should never be pursued during an active asthma attack or acute exacerbation. The combination of air trapping, bronchospasm, and the stress of the hyperbaric environment creates an unsafe situation. HBOT for any indication should be deferred until asthma is stable and well-controlled.

Asthmatics Who Need HBOT for Other Indications

An asthmatic patient who has a diabetic wound, radiation injury, or other approved HBOT indication doesn’t need to forgo treatment because of their asthma. With appropriate pulmonary evaluation confirming current control and absence of significant air trapping, most stable asthmatic patients can safely receive HBOT for other indications. Communication between the pulmonologist and the hyperbaric physician is important. The side effects and contraindications guide covers pulmonary contraindications in detail.

What Actually Works for Asthma

For asthma management, well-evidenced treatments have proven efficacy that HBOT cannot approach. Inhaled corticosteroids remain the cornerstone of chronic asthma management, with extensive trial evidence for reducing inflammation, exacerbation frequency, and mortality risk. Short-acting beta-agonists (SABAs) provide effective rescue bronchodilation. For severe allergic or eosinophilic asthma, biologic therapies (omalizumab, mepolizumab, dupilumab, and others) have transformed outcomes for refractory patients. Allergen avoidance and trigger management are evidence-based components of all asthma care plans.

The alternatives to HBOT article is worth reviewing if you’re exploring non-standard options for asthma management. The fundamental recommendation is to work with a pulmonologist to optimize standard therapy before considering unproven adjuncts.

Environmental and Allergen Factors in Asthma

Asthma management fundamentally depends on identifying and managing triggers. Common triggers include allergens (dust mites, pet dander, mold, pollen), irritants (tobacco smoke, air pollution, strong odors), respiratory infections, exercise, cold air, and stress. No amount of HBOT addresses the continued exposure to triggers that is often the primary driver of poor asthma control. Environmental control measures, allergen immunotherapy where appropriate, and trigger identification and avoidance are foundational to asthma management and should precede and accompany any consideration of adjunctive therapies.

The point is relevant because some asthma patients pursue HBOT hoping it will address their inflammatory disease at a level that allows reduced dependence on medications or reduced sensitivity to triggers. The evidence does not support this expectation, and pursuing HBOT while neglecting environmental control measures is unlikely to produce meaningful benefit.

Biologic Therapies: The Real Frontier for Severe Asthma

For patients with severe, refractory asthma who are seeking treatments beyond standard controller medications, biologic therapies represent the most evidence-based frontier. Biologics including omalizumab (anti-IgE), mepolizumab, benralizumab, and reslizumab (anti-eosinophil approaches), and dupilumab (anti-IL-4/13) have transformed outcomes for appropriately selected severe asthma patients. These are precisely targeted immunological interventions with substantially more evidence than HBOT for the specific inflammatory mechanisms driving severe asthma. If you have severe or refractory asthma and haven’t been evaluated for biologic therapy eligibility, that conversation with a pulmonologist or allergist should take priority over HBOT exploration.

The Emotional Dimension of Seeking Alternative Treatments

Asthma that isn’t well-controlled despite appropriate treatment is frightening and exhausting. The desire to try something different is understandable. If you’re in this situation, the most important thing you can do is work with a specialist who has experience managing refractory asthma and can systematically evaluate whether there are optimization opportunities in your current treatment before adding unproven adjuncts. Often, there are: inhaler technique issues, adherence problems, unrecognized triggers, comorbid conditions (vocal cord dysfunction, GERD, obesity, sleep apnea) that are driving symptoms. Addressing these systematically is more likely to produce meaningful improvement than adding HBOT to a suboptimally managed regimen.

Obesity, Asthma, and HBOT Safety

Obesity is a significant comorbidity in asthma and independently impairs lung function, increases airway inflammation, and worsens sleep-disordered breathing. Many obese asthmatics have non-eosinophilic asthma driven partly by mechanical and inflammatory effects of adipose tissue rather than classical allergic mechanisms, which responds less well to standard controller medications. In the context of HBOT, obesity adds logistical considerations: chamber size limitations, positioning comfort for extended 90-minute sessions, and the effect of obesity on breathing mechanics in a pressurized environment are practical factors to discuss with the hyperbaric facility before scheduling treatment.

For obese asthmatic patients pursuing HBOT for another indication, working with the hyperbaric team to ensure appropriate chamber selection and session management is worth addressing proactively. Weight loss, which independently improves asthma control in obese patients, remains a high-value intervention that is far more evidence-based for asthma management than HBOT.

Monitoring During HBOT for Asthmatics with Other Indications

Asthmatic patients receiving HBOT for an approved indication (wound healing, radiation injury, osteomyelitis) should have their respiratory status monitored throughout the course. This means having their rescue inhaler available at every session, communicating any increase in respiratory symptoms to the hyperbaric staff immediately, and having a protocol in place for managing bronchospasm in the chamber if it occurs. Acute bronchospasm during a session requires controlled depressurization, which is slower than a normal emergency exit, making it important that the hyperbaric team is prepared and the patient has discussed their asthma history, current medications, and trigger patterns before the first session.

Regular check-ins with the pulmonologist during a multi-week HBOT course allow any emerging respiratory changes to be addressed promptly. An asthmatic patient whose condition is well-managed before starting HBOT can usually complete a full course safely with appropriate monitoring and communication between the pulmonology and hyperbaric medicine teams.

Sources

• Mayo Clinic. “Hyperbaric oxygen therapy.” Mayo Clinic, 2024. Mayo Clinic: Hyperbaric Oxygen Therapy
• U.S. Food and Drug Administration. “Hyperbaric Oxygen Therapy: Don’t Be Misled.” FDA, 2021. FDA: Hyperbaric Oxygen Therapy Consumer Update
• Undersea and Hyperbaric Medical Society. “HBO Therapy Indications.” UHMS. UHMS: Approved HBO Indications
• American Academy of Allergy, Asthma and Immunology. “Asthma Overview.” AAAAI, 2024. American Academy of Allergy, Asthma & Immunology

References

1. Undersea and Hyperbaric Medical Society. “Hyperbaric Oxygen Therapy Indications.” 14th Edition, 2019. uhms.org
2. Thom SR. “Hyperbaric oxygen: its mechanisms and efficacy.” Plastic and Reconstructive Surgery. 2011;127(Suppl 1):131S-141S. DOI: 10.1097/PRS.0b013e3181fbe2bf
3. Centers for Medicare & Medicaid Services. “National Coverage Determination for Hyperbaric Oxygen Therapy.” NCD 20.29. cms.gov

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website